PF 04254644

PF 04254644 is an orally active c-Met inhibitor. PF 04254644 inhibits mesenchymal transfer factor/hepatocyte growth factor receptor. PF 04254644 induces myocardial degeneration in rats. PF 04254644 may be used in research on cardiovascular disease and cancer[1][2].

Product Specifications

CAS Number

[959584-91-9]

UNSPSC

12352005

Target

C-Met/HGFR

Related Pathways

Protein Tyrosine Kinase/RTK

Field of Research

Cancer; Cardiovascular Disease

Smiles

C[C@@H](C1=CC2=C(N=CC=C2)C=C1)C3=NN=C4N3N=C(C5=CN(C)N=C5)C=C4

Molecular Formula

C20H17N7

Molecular Weight

355.40

References & Citations

[1]Cui JJ, et al. Lessons from (S) -6- (1- (6- (1-methyl-1H-pyrazol-4-yl) -[1,2,4]triazolo[4,3-b]pyridazin-3-yl) ethyl) quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats. J Med Chem. 2013 Sep 12;56 (17) :6651-65.|[2]Hu W, et al. A tyrosine kinase inhibitor-induced myocardial degeneration in rats through off-target phosphodiesterase inhibition. J Appl Toxicol. 2012 Dec;32 (12) :1008-20.